MX384442B - Tratamiento de la demencia. - Google Patents
Tratamiento de la demencia.Info
- Publication number
- MX384442B MX384442B MX2019002429A MX2019002429A MX384442B MX 384442 B MX384442 B MX 384442B MX 2019002429 A MX2019002429 A MX 2019002429A MX 2019002429 A MX2019002429 A MX 2019002429A MX 384442 B MX384442 B MX 384442B
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- treatment
- dementia
- methylthioninium
- memantine
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 3
- 206010012289 Dementia Diseases 0.000 title 1
- 102000012440 Acetylcholinesterase Human genes 0.000 abstract 1
- 108010022752 Acetylcholinesterase Proteins 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 229940022698 acetylcholinesterase Drugs 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 abstract 1
- 229960004640 memantine Drugs 0.000 abstract 1
- -1 methylthioninium compound Chemical class 0.000 abstract 1
- 230000000946 synaptic effect Effects 0.000 abstract 1
- 230000005062 synaptic transmission Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Valve Device For Special Equipments (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1614834.8A GB201614834D0 (en) | 2016-09-01 | 2016-09-01 | Treatment of dementia |
| PCT/EP2017/071437 WO2018041739A1 (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019002429A MX2019002429A (es) | 2019-07-08 |
| MX384442B true MX384442B (es) | 2025-03-14 |
Family
ID=57139937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002429A MX384442B (es) | 2016-09-01 | 2017-08-25 | Tratamiento de la demencia. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10842796B2 (enExample) |
| EP (1) | EP3506904B1 (enExample) |
| JP (1) | JP7066679B2 (enExample) |
| KR (1) | KR102559354B1 (enExample) |
| CN (1) | CN109890391B (enExample) |
| AU (1) | AU2017318333B2 (enExample) |
| DK (1) | DK3506904T3 (enExample) |
| ES (1) | ES2847929T3 (enExample) |
| GB (1) | GB201614834D0 (enExample) |
| HR (1) | HRP20210162T1 (enExample) |
| MX (1) | MX384442B (enExample) |
| MY (1) | MY187564A (enExample) |
| PL (1) | PL3506904T3 (enExample) |
| PT (1) | PT3506904T (enExample) |
| SG (1) | SG11201901125TA (enExample) |
| SI (1) | SI3506904T1 (enExample) |
| WO (1) | WO2018041739A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104119294B (zh) | 2006-03-29 | 2018-10-30 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物的制备方法 |
| MY162313A (en) | 2006-07-11 | 2017-05-31 | Wista Lab Ltd | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| PL3487505T3 (pl) | 2016-07-25 | 2023-10-09 | Wista Laboratories Ltd. | Podawanie i dawkowanie diaminofenotiazyn |
| BR112021000802A2 (pt) * | 2018-07-26 | 2021-04-13 | Wista Laboratories Ltd. | Dosagem otimizada de diaminofenotiazinas em populações |
| CN120148902A (zh) | 2018-09-05 | 2025-06-13 | 云顶道卫思诊断中心有限公司 | 神经系统变性疾病的网络方法 |
| GB201909454D0 (en) * | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| GB202006659D0 (en) * | 2020-05-05 | 2020-06-17 | Wista Lab Ltd | Therapeutic treatments |
| ES2992641T3 (en) * | 2020-05-05 | 2024-12-16 | Wista Lab Ltd | Methylthioninium compounds for use in the treatment of hypoxemia |
| CA3257856A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT) |
| EP4342451A1 (en) * | 2022-09-22 | 2024-03-27 | Galenicum Health SLU | Pharmaceutical compositions and manufacturing methods thereof |
| US20240115579A1 (en) * | 2022-09-22 | 2024-04-11 | Galenicum Health S.L.U. | Pharmaceutical compositions and manufacturing methods thereof |
| US20240300940A1 (en) * | 2023-02-21 | 2024-09-12 | Prosetta Biosciences, Inc. | Phenothiazinyl Compounds and Uses |
| GB202500018D0 (en) | 2025-01-02 | 2025-02-19 | Wista Lab Ltd | Long term dosing of neurodegenerative disorders utilising methylthioninium (mt) containing compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| EP1509232B1 (en) * | 2002-05-31 | 2008-11-19 | H. Lundbeck A/S | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
| WO2006032879A2 (en) | 2004-09-23 | 2006-03-30 | Wista Laboratories Ltd. | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
| CN104119294B (zh) * | 2006-03-29 | 2018-10-30 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物的制备方法 |
| DK2853293T3 (en) * | 2006-03-29 | 2018-01-22 | Wista Lab Ltd | Thioninium compounds and their use |
| FR2899107B1 (fr) * | 2006-03-30 | 2008-06-13 | Neurokin Entpr Unipersonnelle | Utilisation de la (s)-roscovitine pour la fabrication d'un medicament |
| MY162313A (en) | 2006-07-11 | 2017-05-31 | Wista Lab Ltd | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| FR2903696B1 (fr) | 2006-07-12 | 2011-02-11 | Provence Technologies | Procede de purification de composes diaminophenothiazium |
| US9034890B2 (en) * | 2006-11-15 | 2015-05-19 | Steven A. Rich | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases |
| AU2008265045B2 (en) * | 2007-06-19 | 2014-02-27 | Taurx Therapeutics Management Ltd. | Phenothiazine compounds for treating Mild Cognitive Impairment |
| PT2954932T (pt) * | 2007-10-03 | 2018-12-12 | Wista Lab Ltd | Utilização terapêutica de diaminofenotiazinas |
| KR20170061177A (ko) | 2009-09-24 | 2017-06-02 | 위스타 레보레이토리스 리미티드 | 결정질 메틸티오니늄 클로라이드（메틸렌 블루） 수화물 |
| WO2011036561A2 (en) | 2009-09-24 | 2011-03-31 | Wis Ta Laboratories Ltd. | Process |
| KR101888713B1 (ko) | 2011-02-11 | 2018-08-14 | 위스타 레보레이토리스 리미티드 | 페노티아진 디아미늄 염 및 이의 용도 |
| CN102936244B (zh) * | 2012-12-04 | 2015-02-04 | 合肥工业大学 | 一种他克林-吩噻嗪异二联体类化合物及其制备方法 |
-
2016
- 2016-09-01 GB GBGB1614834.8A patent/GB201614834D0/en not_active Ceased
-
2017
- 2017-08-25 WO PCT/EP2017/071437 patent/WO2018041739A1/en not_active Ceased
- 2017-08-25 HR HRP20210162TT patent/HRP20210162T1/hr unknown
- 2017-08-25 SI SI201730630T patent/SI3506904T1/sl unknown
- 2017-08-25 SG SG11201901125TA patent/SG11201901125TA/en unknown
- 2017-08-25 JP JP2019511720A patent/JP7066679B2/ja active Active
- 2017-08-25 ES ES17761842T patent/ES2847929T3/es active Active
- 2017-08-25 EP EP17761842.8A patent/EP3506904B1/en active Active
- 2017-08-25 CN CN201780067154.4A patent/CN109890391B/zh active Active
- 2017-08-25 PL PL17761842T patent/PL3506904T3/pl unknown
- 2017-08-25 MY MYPI2019001119A patent/MY187564A/en unknown
- 2017-08-25 KR KR1020197009175A patent/KR102559354B1/ko active Active
- 2017-08-25 US US16/329,611 patent/US10842796B2/en active Active
- 2017-08-25 DK DK17761842.8T patent/DK3506904T3/da active
- 2017-08-25 AU AU2017318333A patent/AU2017318333B2/en active Active
- 2017-08-25 PT PT177618428T patent/PT3506904T/pt unknown
- 2017-08-25 MX MX2019002429A patent/MX384442B/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017318333B2 (en) | 2023-05-11 |
| GB201614834D0 (en) | 2016-10-19 |
| JP2019526571A (ja) | 2019-09-19 |
| PL3506904T3 (pl) | 2021-07-26 |
| ES2847929T3 (es) | 2021-08-04 |
| CN109890391B (zh) | 2023-01-31 |
| SI3506904T1 (sl) | 2021-03-31 |
| EP3506904A1 (en) | 2019-07-10 |
| MX2019002429A (es) | 2019-07-08 |
| PT3506904T (pt) | 2021-02-02 |
| US10842796B2 (en) | 2020-11-24 |
| CN109890391A (zh) | 2019-06-14 |
| KR102559354B1 (ko) | 2023-07-26 |
| AU2017318333A1 (en) | 2019-04-18 |
| MY187564A (en) | 2021-09-30 |
| JP7066679B2 (ja) | 2022-05-13 |
| DK3506904T3 (da) | 2021-01-04 |
| WO2018041739A1 (en) | 2018-03-08 |
| SG11201901125TA (en) | 2019-03-28 |
| KR20190045273A (ko) | 2019-05-02 |
| EP3506904B1 (en) | 2020-12-09 |
| US20190192530A1 (en) | 2019-06-27 |
| HRP20210162T1 (hr) | 2021-03-19 |
| CA3034625A1 (en) | 2018-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019002429A (es) | Tratamiento de la demencia. | |
| BR112017005104A2 (pt) | derivado de 5,6-di-hidro-4h-benzotieno-[2,3-d]azepina | |
| EA201790271A1 (ru) | Ингибиторы гликозидазы | |
| DOP2016000195A (es) | Compuestos | |
| MX2018008105A (es) | Compuestos inhibidores de metaloenzima. | |
| IL263433A (en) | Methods for treating alzheimer's disease | |
| WO2019173795A3 (en) | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease | |
| WO2016097315A3 (en) | Blood brain barrier transport molecules and uses thereof | |
| PH12019500196A1 (en) | Compounds and compositions and uses thereof | |
| MX380252B (es) | Crenezumab para usarse en el tratamiento de enfermedad de alzheimer. | |
| MX378940B (es) | Trastornos neurodegenerativos. | |
| MA48939B1 (fr) | Compositions comprenant des souches bactériennes | |
| MX380290B (es) | Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos. | |
| BR112019027387A8 (pt) | Composições imunogênicas | |
| DK3463351T3 (da) | Behandling til parkinsons sygdom | |
| MX378739B (es) | Compuestos de 2-oxindol. | |
| WO2015109318A3 (en) | Therapeutic methods | |
| EP3429569A4 (en) | METHOD FOR PREVENTING OR TREATING PARKINSON'S DISEASE BY PARNY SYNTHESIS | |
| LT3413870T (lt) | Igmesinas, skirtas panaudoti alzheimerio ligos gydymui | |
| BR112019007214A2 (pt) | composições do apilimode e métodos para uso do mesmo no tratamento do mal de alzheimer | |
| PH12017501955A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease | |
| MX2019001804A (es) | Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos. | |
| WO2016182812A8 (en) | Activation of neuronal store-operated calcium entry pathway for the treatment of alzheimer's disease | |
| BR112018012126A2 (pt) | ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante? | |
| IL262902A (en) | Prion protein-dendrimer conjugates for use in treatment of alzheimer disease |